model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Gemini-3-Pro,protocolSection.identificationModule.nctId,TP,TP,NCT03408730,NCT03408730,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].domain,EV,EV,,EU Clinical Trials,,,,SecondaryIdDomain,protocolSection.identificationModule.secondaryIdInfos.domain,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.briefTitle,TP,TP,Lot-to-lot Consistency of Sci-B-Vac™ in Adults,Immunogenicity and Safety of a 3-Antigen Hepatitis B Virus (HBV) vs a Single-Antigen HBV Vaccine Among Young Adults,True,0.78,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.officialTitle,TP,TP,A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT),"Phase 3, Double-Blinded, Randomized, Multicenter, Lot-to-Lot Consistency Study With 3 Parallel Groups of 3A-HBV and a Comparator Group of 1A-HBV",True,0.87,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.briefSummary,TP,TP,A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults,"This phase 3 randomized clinical trial evaluates the manufacturing equivalence, immunogenicity, and safety of a 3-antigen hepatitis B virus (HBV) vaccine compared with a single-antigen HBV vaccine in healthy adults aged 18 to 45 years. The study tests the hypothesis that the 3-antigen vaccine demonstrates consistency across manufacturing lots and noninferior seroprotection rates compared to the standard single-antigen vaccine.",True,0.9,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.detailedDescription,TP,TP,The primary objective of the study is to verify that the manufacturing equivalence of Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose regimen of Sci-B-Vac™ to a three-dose regimen of Engerix-B® in adults.,"The study design was a phase 3, double-blinded, randomized, multicenter, lot-to-lot consistency study involving healthy adults aged 18 to 45 years. Participants were randomized (1:1:1:1) to receive one of three independent consecutive lots of the 3-antigen HBV (3A-HBV) vaccine or a comparator single-antigen (1A-HBV) vaccine. The 3A-HBV vaccine contains pre-S1, pre-S2, and S antigens produced in mammalian cells, whereas the comparator contains only the S antigen. Vaccines were administered intramuscularly on days 0, 28, and 168. The primary efficacy endpoint was the manufacturing equivalence of the three 3A-HBV lots, assessed by the geometric mean concentration (GMC) of anti-HBs antibodies 4 weeks after the third injection. Secondary endpoints included demonstrating that the seroprotection rate (SPR) of the pooled 3A-HBV vaccine was noninferior to that of the 1A-HBV vaccine at day 196, as well as comparing safety and reactogenicity profiles between the two vaccine types.",True,0.78,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.conditions,TP,FP,['Hepatitis B Vaccines'],"['Hepatitis B', 'Hepatitis B Virus Infection']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.keywords,TP,TP,['Hepatitis B Vaccines'],"['Hepatitis B Vaccines', 'Immunogenicity', 'Safety', '3-antigen HBV vaccine', 'Sci-B-Vac', 'Lot-to-lot consistency', 'Healthy Adults']",True,1.0,superset,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.phases,TP,TP,['PHASE3'],['PHASE3'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.masking,TP,FP,TRIPLE,DOUBLE,False,0.65,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,All study personnel providing clinical assessments and participants were blind to the vaccine allocation.,,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,FP,"['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']","['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']",False,0.6666666666666666,partial,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.enrollmentInfo.count,TP,TP,2838,2838,True,1.0,exact,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Geometric Mean Concentration (GMC) of Anti-HBs,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Seroprotection Rate (SPR),,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Proportion of Participants Achieving Anti-HBs Concentrations ≥ 100 mIU/mL,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Measurement of antibody response levels.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,Proportion of participants achieving anti-HBs concentrations of at least 10 mIU/mL.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,Proportion of participants reaching antibody concentrations of at least 100 mIU/mL.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,Day 168 (after 2 vaccinations) and Day 336,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,Day 168 (after 2 vaccinations) and Day 336,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,"Day 168, Day 196, and Day 336",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Any gender
* Age 18-45 years
* Healthy, as determined by a physical examination and values of laboratory tests
* If female, either is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), is of childbearing potential and must agree to use an adequate birth control method
* Able and willing to give informed consent

Exclusion Criteria:

* Previous vaccination with any Hep B vaccine (HBV) (licensed or experimental)
* Treatment by immunosuppressant within 30 days of enrollment
* History of immunological function impairment
* Pregnancy or breastfeeding
* Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment
* Immunization with inactivated vaccines (e.g. influenza) within 2 week prior to enrolment
* Has received blood products or immunoglobulin within 90 days of enrollment or is likely to require blood products during the study period
* Subject in another clinical trial with an investigational drug or a biologic within 30 days of enrollment
* Has received granulocyte-macrophage colony stimulating factor (G/GM-CSF) or erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF or erythropoietin during the study period
* Any history of cancer requiring chemotherapy or radiation within 5 years of randomization or current disease.
* Any skin abnormality or tattoo that would limit post-vaccination injection site assessment
* History of allergic reactions or anaphylactic reaction to any vaccine component
* Unwilling, or unable in the opinion of the investigator, to comply with study requirements
* Immediate family members of study center staff
* Current or past hepatitis B infection or prior vaccination as evidenced by HBV markers
* Known hepatitis C infection or positive Hepatitis C serology at screening, unless treated and cured
* Known human immunodeficiency virus (HIV) infection or positive HIV serology at screening
* Renal impairment with Glomerular Filtration Rate (GFR) \<90 mL/min/ 1.73 m2 at screening
* BMI ≥ 35
* Uncontrolled hypertension
* Diagnosis of Type 1 or Type 2 diabetes or HbA1C ≥ 6.5% at screening
* Any laboratory test abnormality that would be considered of Grade 1 severity or above as per FDA guidelines for grading clinical laboratory abnormalities and is considered as clinically significant by the investigator.","Inclusion Criteria:
* Healthy adults aged 18 to 45 years at the time of the first vaccination
* In stable health
* Provided written informed consent

Exclusion Criteria:
* A complete list of exclusion criteria is presented in eMethods 1 in Supplement 2 (not provided in the article text)",True,0.86,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,True,True,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.maximumAge,TP,TP,45 Years,45 Years,True,1.0,exact,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.stdAges,TP,TP,['ADULT'],['ADULT'],True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
